Abstract
Introduction
Neuronal ceroid lipofuscinoses (CLN) are neurodegenerative disorders among the most frequent, inherited as an autosomal recessive trait. Affected patients can present with progressive decline in cognitive and motor functions, seizures, a shortened life span and visual deficiency. CLN2 is one of the rare CLN that benefits from treatment by cerliponase alpha an enzyme replacement therapy. Preliminary results on treated animal models have shown delayed neurological signs and prolonged life span. However, cerliponase alpha did not prevent vision loss or retinal degeneration in those animal models. Cerliponase alpha has currently been delivered to a few CLN2-affected patients. We report the case of one patient suffering from CLN2 treated with intracerebroventricular infusions of cerliponase alpha 300 mg every two weeks. Evolution of his retinal function was assessed by three successive flash-ERG and flash-VEP recordings throughout his treatment over a 4-year period.
Results
Before treatment at the age of 4 years 5 months, patient’s retinas were normal (normal fundi and normal flash-ERG). After 29 infusions at the age of 6 years 10 months, a-wave combined response was absent, while cone and flicker responses were normal. After 80 infusions at the age of 8 years 9 months, a-wave cone response was absent with b-wave peak time increased, and no combined response.
Comments
Despite treatment, our patient’s retinas showed a progressive abnormal and inhomogeneous function. Rods function was altered first, then the scotopic system and afterward, the cones. This result differs from those recorded in animal models. The relative preservation of cone functioning for a while could not be unequivocally attributed to enzyme replacement therapy as we lack comparison with the evolution of flash-ERGs recorded in untreated subjects.
Similar content being viewed by others
Abbreviations
- cd:
-
Candela
- cd/m2 :
-
Candela per meter square
- cd.s/m2 :
-
Candela.second per meter square
- CLN:
-
Neuronal ceroid lipofuscinoses
- CLN2:
-
Late infantile neuronal ceroid lipofuscinosis (Jansky–Bielschowsky)
- CLN2 :
-
CLN2 Gene
- ERG:
-
Electroretinogram
- VEP:
-
Visual evoked potential
References
Menache CC., Haenggeli Ch-A., and Safran AB., (2004) Affections du métabolisme général à expression neuro-ophtalmologique., in Neuro-Ophtalmologie - Rapport de la Société Française d'Ophtalmologie, Safran AB., Editor Masson: Paris. p. 425–454
Mukherjee AB et al (2019) Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol Neurodegener 14(1):4
Saudubray JM, Van den Berghe G, Walters JH (2012) Inborn metabolic diseases. Diagnosis and treatment, 5th edn. Springer-Verlag, Heidelberg
Nelvagal HR et al (2019) Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis 9:165570
Perez-Poyato MS et al (2013) Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol 28(4):470–478
Nickel M et al (2018) Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2(8):582–590
Williams RE et al (2017) Management strategies for CLN2 disease. Pediatr Neurol 69:102–112
Sima N et al (2018) Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis 13(1):54
Mole SE et al (2019) Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol 18(1):107–116
Kohlschutter A et al (2019) Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs 33(4):315–325
Markham A (2017) Cerliponase alfa: first global approval. Drugs 77(11):1247–1249
Katz ML et al (2014) Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J Neurosci Res 92(11):1591–1598
Sanders DN et al (2011) A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis. Genes Brain Behav 10(7):798–804
Cherukuri A et al (2018) Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a phase 1/2 study. Clin Immunol 197:68–76
Vuillemenot BR et al (2014) Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 277(1):49–57
Whiting RE et al (2016) Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease. Exp Eye Res 146:276–282
Schulz A et al (2018) Study of intraventricular cerliponase Alfa for CLN2 disease. N Engl J Med 378(20):1898–1907
Kohlschutter A, Schulz A (2016) CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev 13(Suppl 1):682–688
Specchio N, Pietrafusa N, Trivisano M (2020) Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag 16:213–222
Lau JC et al (2018) Image-guided Ommaya reservoir insertion for intraventricular chemotherapy: a retrospective series. Acta Neurochir (Wien) 160(3):539–544
Wang A et al (2019) Placement of ommaya reservoirs using electromagnetic neuronavigation and neuroendoscopy: a retrospective study with cost-benefit analysis. World Neurosurg 122:e723–e728
Fulton AB, Hartmann EE, Hansen RM (1989) Electrophysiologic testing techniques for children. Doc Ophthalmol 71(4):341–354
Bradshaw K, Hansen R, Fulton A (2004) Comparison of ERGs recorded with skin and corneal-contact electrodes in normal children and adults. Doc Ophthalmol 109(1):43–55
Hamilton R, Graham K (2016) Effect of shorter dark adaptation on ISCEV standard DA 0.01 and DA 3 skin ERGs in healthy adults. Doc Ophthalmol 133(1):11–9
Bach M, Meroni C, Heinrich SP (2020) ERG shrinks by 10% when reducing dark adaptation time to 10 min, but only for weak flashes. Doc Ophthalmol 141(1):57–64
Odom JV et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133(1):1–9
Weleber RG (1998) The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye (Lond) 12(Pt 3b):580–590
Quagliato E et al (2017) Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. Arq Bras Oftalmol 80(4):215–219
Dozieres-Puyravel B et al (2020) Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol 62(4):528–530
Mohand-Said S et al (2001) Rod-cone interactions: developmental and clinical significance. Prog Retin Eye Res 20(4):451–467
Yang Y et al (2009) Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther 17(5):787–795
Le Gargasson JF et al (1990) Visual electrophysiology in 101 children with encephalopathy. J Fr Ophtalmol 13(8–9):441–448
Specchio N et al (2017) Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia 58(8):1380–1388
Whiting RE et al (2014) Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res 125:164–172
Mowat FM et al (2008) Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol Vis 14:2518–2527
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Statement of human rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Statement on the welfare of animals
This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Conflicts of interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rigaudière, F., Nasser, H., Pichard-Oumlil, S. et al. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report. Doc Ophthalmol 143, 99–106 (2021). https://doi.org/10.1007/s10633-021-09825-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10633-021-09825-z